Spyre Therapeutics, Inc. (SYRE) AI Stock Analysis
SYRE AI stock analysis summary
AI ResearchSpyre Therapeutics, Inc. (SYRE) is a biotechnology company focused on advancing novel therapeutics for inflammatory bowel disease. The company generated $0 in revenue over the trailing twelve months ended June 30, 2026, posting an EPS of -$1.92. Its balance sheet remains liquid with $1.15B in cash and short-term investments.
- Market cap
- $7.47B
- Revenue (TTM)
- $0
- P/E
- —
- 1Y return
- 259.3% S&P 500 16.8%
- Avg. target
- $119.93 50.1% vs last close
Bull case
- The balance sheet is well capitalized with $1.15B in cash and short-term investments and a current ratio of 18.53 as of June 30, 2026.
- Wall Street sentiment is positive, with 16 Strong Buy ratings and a mean price target of $119.93 representing 50.1% upside over the last close.
- Shares have demonstrated strong recent market momentum, delivering a 1-year return of 259.3% compared to 16.8% for the S&P 500.
Bear case
- The company generates no commercial product sales, posting $0 in revenue over the trailing twelve months and consensus estimates of $0 revenue through next fiscal year.
- Ongoing development drives heavy cash outflows, including a FY2024 net income of -$208.0M and free cash flow of -$157.4M.
- Financing operations has resulted in substantial dilution, with a five-year share count change of 4191.8% as of FY2025.
What Spyre Therapeutics does
Spyre Therapeutics, Inc., based in Waltham, Massachusetts, is a biotechnology company advancing novel therapeutics for inflammatory bowel disease (IBD) at the preclinical stage. Originally founded in 2013 and formerly known as Aeglea BioTherapeutics, Inc., the company rebranded in November 2023. Spyre's pipeline is led by SPY001, a human monoclonal antibody targeting the a4ß7 integrin for ulcerative colitis and Crohn's disease. Its development programs also include SPY002 targeting TL1A, the combination therapy SPY120, anti-IL-23 antibody SPY003, SPY004 exploring novel mechanisms of action, and additional antibody combinations SPY130 and SPY230.
Growth and profitability
Revenue stood at $3.9M in FY2018 and reached $18.7M in FY2021 before declining to $2.3M in FY2022. In FY2023, revenue fell 62.0% to $886,000 with a net income of -$338.8M and an operating margin of -27348.0%. In FY2024, revenue was unchanged at $886,000 with 0.0% growth, a gross margin of 100.0%, and a net income of -$208.0M alongside R&D expenses of $162.8M. For the trailing twelve months ended June 30, 2026, revenue was $0 and EPS was -$1.92, while quarterly earnings growth fell 99.7% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Spyre Therapeutics held $1.15B in cash and short-term investments, with total assets of $1.17B and shareholders' equity of $1.10B. The company reported a current ratio of 18.53. Operating cash flow in FY2024 was -$157.4M, equal to its free cash flow of -$157.4M. To fund operations and clinical pipelines, share count increased 4191.8% over five years as of FY2025.
Valuation and performance
Spyre Therapeutics has a market cap of $7.47B and an enterprise value of $6.78B. The company trades at a price-to-sales ratio of 650.2x and a price-to-book ratio of 8.1x, compared to a median price-to-sales ratio of 4.1x for its US-listed Healthcare peers. The peer group median EV to EBITDA is 12.0x. Over the past year, SYRE returned 259.3%, outperforming the S&P 500 (SPY) return of 16.8%, though its 5-year return fell 60.9% versus an 83.0% gain for SPY.
What analysts expect
Wall Street coverage includes 16 Strong Buy, 1 Buy, and 1 Hold ratings. The consensus mean price target is $119.93, representing a 50.1% upside compared to the last close of $79.90. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$2.85 on $0 revenue. For the following fiscal year, 14 analysts project an EPS of -$3.52 and revenue of $0. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 3, 2026.
Key risks and what to watch
- The stock has a beta of 3.11 and short interest represents 15.4% of the float, pointing to elevated volatility.
- Quarterly earnings growth declined 99.7% year-over-year in the period ending June 30, 2026.
- Annual R&D expense reached $162.8M in FY2024, continuing to create sustained losses without incoming revenue.
- The valuation shows a price-to-sales multiple of 650.2x, significantly higher than the 4.1x median for US-listed Healthcare peers.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this SYRE AI stock analysis
This page is an AI-written research summary of Spyre Therapeutics, Inc. (SYRE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: SYRE income statement, SYRE balance sheet, SYRE key metrics, SYRE analyst forecast, SYRE chart. See the SYRE stock overview for the latest quote and news.
SYRE AI stock analysis FAQ
Does Spyre Therapeutics pay a dividend?
No, Spyre Therapeutics does not pay a dividend.
What is Spyre Therapeutics' cash and liquidity position?
As of June 30, 2026, the company held $1.15B in cash and short-term investments, with a current ratio of 18.53 and shareholders' equity of $1.10B.
What do analysts project for SYRE's earnings?
Analysts expect an EPS of -$2.85 for the fiscal year ending December 31, 2026, and an EPS of -$3.52 for the next fiscal year, with revenue estimated at $0 in both periods.
What is the consensus price target for SYRE stock?
The mean analyst price target is $119.93, which is 50.1% above the last closing price of $79.90 on October 16, 2026.